Liven Pharma Limited (PSX:LIVEN)
Pakistan
· Delayed Price · Currency is PKR 32.68
-1.74 (-5.06%)
At close: Mar 6, 2026
Liven Pharma Income Statement
Financials in millions PKR. Fiscal year is July - June.
Millions PKR. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Revenue | 84.62 | 127.27 | 245.09 | - | - | - | Upgrade
|
| Revenue Growth (YoY) | -75.90% | -48.07% | - | - | - | - | Upgrade
|
| Cost of Revenue | 81.16 | 111.45 | 182.96 | - | - | - | Upgrade
|
| Gross Profit | 3.45 | 15.82 | 62.14 | - | - | - | Upgrade
|
| Selling, General & Admin | 393.31 | 389.03 | 19.14 | 2.12 | 2.95 | 2.1 | Upgrade
|
| Other Operating Expenses | 114.48 | 88.84 | 1.23 | - | - | - | Upgrade
|
| Operating Expenses | 537.46 | 507.53 | 20.37 | 15.22 | 17.51 | 18.19 | Upgrade
|
| Operating Income | -534 | -491.71 | 41.77 | -15.22 | -17.51 | -18.19 | Upgrade
|
| Interest Expense | -2.03 | -0.73 | -0.02 | - | - | - | Upgrade
|
| Interest & Investment Income | 0.31 | 0.31 | - | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -109.37 | -0.06 | -0 | -0 | -0 | -0 | Upgrade
|
| EBT Excluding Unusual Items | -645.09 | -492.19 | 41.74 | -15.23 | -17.51 | -18.19 | Upgrade
|
| Pretax Income | -645.09 | -492.19 | 41.74 | -15.23 | -17.51 | -18.19 | Upgrade
|
| Income Tax Expense | 60.55 | 92.27 | - | -2.9 | -3.22 | -3.55 | Upgrade
|
| Net Income | -705.64 | -584.46 | 41.74 | -12.33 | -14.29 | -14.63 | Upgrade
|
| Net Income to Common | -705.64 | -584.46 | 41.74 | -12.33 | -14.29 | -14.63 | Upgrade
|
| Shares Outstanding (Basic) | 94 | 70 | 0 | 12 | 12 | 12 | Upgrade
|
| Shares Outstanding (Diluted) | 94 | 70 | 0 | 12 | 12 | 12 | Upgrade
|
| Shares Change (YoY) | 417.79% | 174375.69% | -99.67% | - | - | - | Upgrade
|
| EPS (Basic) | -7.49 | -8.37 | 1043.60 | -1.02 | -1.18 | -1.21 | Upgrade
|
| EPS (Diluted) | -7.49 | -8.37 | 1043.60 | -1.02 | -1.18 | -1.21 | Upgrade
|
| Free Cash Flow | -24.98 | -24.56 | 13.8 | -2.27 | -2.26 | -6.79 | Upgrade
|
| Free Cash Flow Per Share | -0.27 | -0.35 | 345.08 | -0.19 | -0.19 | -0.56 | Upgrade
|
| Gross Margin | 4.08% | 12.43% | 25.35% | - | - | - | Upgrade
|
| Operating Margin | -631.09% | -386.34% | 17.04% | - | - | - | Upgrade
|
| Profit Margin | -833.93% | -459.22% | 17.03% | - | - | - | Upgrade
|
| Free Cash Flow Margin | -29.53% | -19.30% | 5.63% | - | - | - | Upgrade
|
| EBITDA | -504.32 | -465.93 | 64.93 | -2.12 | -2.95 | -2.1 | Upgrade
|
| EBITDA Margin | - | - | 26.49% | - | - | - | Upgrade
|
| D&A For EBITDA | 29.68 | 25.78 | 23.16 | 13.1 | 14.56 | 16.08 | Upgrade
|
| EBIT | -534 | -491.71 | 41.77 | -15.22 | -17.51 | -18.19 | Upgrade
|
| EBIT Margin | - | - | 17.04% | - | - | - | Upgrade
|
| Advertising Expenses | - | 3.26 | 0.12 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.